Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights – IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...